15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $4.3B | -$356M | 0.0% | -10.1% | -8.2% | -3.1% | $1.3B | $5.4B | $1.4B |
| 2024 | $4.1B | $560M | 0.0% | 17.6% | 13.7% | 4.7% | $1.4B | $6.1B | $2.4B |
| 2023 | $3.8B | $415M | 0.0% | 15.1% | 11.1% | 3.6% | $1.1B | $5.7B | $1.5B |
| 2022 | $3.7B | -$224M | 0.0% | -1.8% | -7.3% | -2.1% | $1.2B | $5.7B | $881M |
| 2021 | $3.1B | -$330M | 0.0% | 5.5% | -8.3% | -2.7% | $751M | $6.0B | $591M |
| 2020 | $2.4B | $239M | 0.0% | 16.0% | 6.5% | 3.7% | $885M | $2.1B | $1.1B |
| 2019 | $2.2B | $523M | 0.0% | 24.6% | 16.8% | 9.4% | $736M | $1.6B | $637M |
| 2018 | $1.9B | $447M | 0.0% | 32.5% | 16.2% | 8.6% | $779M | $1.6B | $310M |
| 2017 | $1.6B | $488M | 0.0% | 32.7% | 18.0% | 9.5% | — | $1.6B | $386M |
| 2016 | $1.5B | $397M | 0.0% | 39.8% | 21.1% | 8.3% | — | $2.0B | $366M |
| 2015 | — | $330M | — | — | 19.3% | 9.9% | — | $1.2B | $989M |
| 2014 | — | $58M | — | — | 4.3% | 1.7% | — | $1.3B | $684M |
| 2013 | — | $216M | — | — | 16.7% | 9.7% | — | $550M | $637M |
| 2012 | — | $289M | — | — | 25.7% | 14.7% | — | $457M | $387M |
| 2011 | — | $125M | — | — | 64.8% | 49.3% | — | $0 | $82M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $1.2B | $193M | 0.0% | 20.5% | 4.0% | 1.7% | $398M | $4.4B | $1.6B |
| Mar '26 | $1.1B | $293M | 0.0% | 31.5% | 6.5% | 2.5% | $389M | $5.4B | $1.8B |
| Dec '25 | $1.2B | $203M | 0.0% | 21.2% | 4.7% | 1.7% | $346M | $5.4B | $1.4B |
| Sep '25 | $1.1B | $251M | 0.0% | 5.1% | 6.4% | 2.2% | $459M | $5.4B | $1.3B |
| Jun '25 | $1.0B | -$719M | 0.0% | -65.6% | -19.4% | -6.6% | $76M | $5.4B | $1.2B |
| Mar '25 | $898M | -$93M | 0.0% | -6.2% | -2.2% | -0.8% | $416M | $5.4B | $1.9B |
| Dec '24 | $1.1B | $191M | 0.0% | 17.5% | 4.7% | 1.6% | $385M | $6.1B | $2.4B |
| Sep '24 | $1.1B | $215M | 0.0% | 24.7% | 5.2% | 1.8% | $388M | $6.1B | $2.2B |
| Jun '24 | $1.0B | $169M | 0.0% | 19.5% | 4.5% | 1.5% | $324M | $5.7B | $1.4B |
| Mar '24 | $902M | -$15M | 0.0% | 7.3% | -0.4% | -0.1% | $260M | $5.7B | $1.4B |
| Dec '23 | $1.0B | $94M | 0.0% | 12.1% | 2.5% | 0.8% | $157M | $5.7B | $1.5B |
| Sep '23 | $972M | $147M | 0.0% | 17.7% | 4.2% | 1.3% | $303M | $5.7B | $1.3B |
| Jun '23 | $957M | $104M | 0.0% | 16.5% | 3.0% | 0.9% | $291M | $5.7B | $1.3B |
| Mar '23 | $893M | $69M | 0.0% | 14.1% | 2.1% | 0.6% | $317M | $5.7B | $1.2B |
| Dec '22 | $972M | -$241M | 0.0% | -27.1% | -7.8% | -2.2% | $333M | $5.7B | $881M |
| Sep '22 | $941M | -$20M | 0.0% | 2.6% | -0.7% | -0.2% | $423M | $5.7B | $839M |
| Jun '22 | $933M | $35M | 0.0% | 9.2% | 1.1% | 0.3% | $291M | $6.0B | $711M |
| Mar '22 | $814M | $2M | 0.0% | 10.8% | 0.0% | 0.0% | $197M | $6.0B | $491M |
| Dec '21 | $897M | -$35M | 0.0% | 5.5% | -0.9% | -0.3% | $168M | $6.0B | $591M |
| Sep '21 | $838M | -$53M | 0.0% | 3.4% | -1.3% | -0.4% | $266M | $6.3B | $672M |
How the market has priced JAZZ against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Jazz Pharmaceuticals Plc's revenue has grown 12.5% per year. These are computed facts, not advice.
As of FY2025, Jazz Pharmaceuticals Plc reported $5.4B of total debt against $1.4B of cash.
In FY2025, gross margin was —, operating margin -10.1%, and net margin -8.3%.
As of Sep '26, Jazz Pharmaceuticals Plc traded at a price-to-earnings ratio of about 20.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.